Tian et al. proposed that high percentage of CD68+PD-L1+ macrophages could serve as a promising biomarker for neoadjuvant immunotherapy in combination with other therapies (including targeted therapy and chemotherapy) in head and neck squamous cell carcinoma (HNSCC) [19]. This evidence concerns the gene CD68 and head and neck squamous cell carcinoma.